Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Moderate Aplastic Anemia
NCT01328587Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Mar 2012
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia and unilineage bone marrow failure disorder, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Proportion of Drug Responders. Started Mar 2012; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemiaunilineage bone marrow failure disorder
Beyond the preview
Go deeper on NCT01328587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01328587.